<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7076512/results/search/test_trace/results.xml">
  <result pre="reflections on nanomedicines currently approved or undergoing investigations for the" exact="treatment" post="of viral infections are also discussed. Finally, the authors"/>
  <result pre="1 presents statistical facts related to the most &quot;burden-generator&quot; viral" exact="infection" post="diseases [3,4,5,6,7]. HIV/AIDS, considered as one of the major"/>
  <result pre="support for the ill person, demanding a higher level of" exact="treatment" post="costs for the HIV-affected households. Consequently, HIV/AIDS causes depletion"/>
  <result pre="complications. In the era of new DAAs, the statement &quot;provide" exact="treatment" post="to HCV-patients&quot; generates savings compared to not provide it."/>
  <result pre="horizon, but in 5–10 years [5]. Economic impact of no" exact="treatment" post="is higher than treatment costs itself. But still, the"/>
  <result pre="years [5]. Economic impact of no treatment is higher than" exact="treatment" post="costs itself. But still, the enthusiasm for DAA therapies,"/>
  <result pre="of the most common infections in humans, with no effective" exact="treatment" post="available at this time. The impact on the health"/>
  <result pre="forms, in most cases limiting methods are applied to local" exact="infection" post="and reducing side effects (pain, manifestations dermis etc.). Also,"/>
  <result pre="at least in part, with the influence of compliance to" exact="treatment" post="and possible under sampling of subpopulations in the data"/>
  <result pre="infection. This leads to recurrent or chronic diseases that require" exact="treatment" post="for longer periods of time [18]. All these limitations"/>
  <result pre="it is monophosphorylated intracellular by viral thymidine kinase during HSV" exact="infection" post="and by a viral phosphotransferase encoded by the UL97"/>
  <result pre="and by mutations in viral DNA polymerase [56]. The conventional" exact="treatment" post="(prophylaxis or therapy) of an influenza virus infection, as"/>
  <result pre="have broad-spectrum antiviral activity represent another possibility against influenza virus" exact="infection" post="[58,59,60]. Briefly, the antiviral mechanism of amantadine is based"/>
  <result pre="attention on therapy. As mentioned in the first section, hepatitis" exact="treatment" post="depends upon the type of hepatitis, therefore different antivirals"/>
  <result pre="both cellular and viral single-stranded RNAs. Antiretroviral therapy—ART—refers to the" exact="treatment" post="with HIV medicines. According to the last updated list"/>
  <result pre="authors describe the pharmacological mechanism of the medicines for HIV" exact="treatment" post="that were included/encapsulated/incorporated into nanomaterials. The representative nucleoside reverse"/>
  <result pre="it is the only nucleotide analogue currently marketed for the" exact="treatment" post="of HIV infection, being active against HIV-1, HIV-2 and"/>
  <result pre="by renal injury [91,92]. Another issue produced by standard HSV" exact="treatment" post="in this case for the topical form of trifluridine"/>
  <result pre="results in fewer side effects with no need of regular" exact="treatment" post="but systemic distribution of the drug. Both methods of"/>
  <result pre="treatment but systemic distribution of the drug. Both methods of" exact="treatment" post="have a common blockage, stratum corneum. To pass through"/>
  <result pre="specified in Section 2, the current antiviral therapy for HSV" exact="infection" post="includes topical formulations of ACV that is unable permeate"/>
  <result pre="between toxicants and therapeutic drugs, creating an important obstacle to" exact="treatment" post="of brain cancer, epilepsy and neuro AIDS [107]. The"/>
  <result pre="required in order to overcome current drawbacks of HCV under-diagnosed" exact="infection" post="as highlighted in the above-mentioned review. The nanotechnology-based tools"/>
  <result pre="al. [164] summarized current strategies and under-development tools for early" exact="diagnosis" post="of HIV. Their review combines the use of nanomaterials"/>
  <result pre="metallic and metal oxide NPs as advanced structures for HIV" exact="detection" post="with possible biosensing strategies targeting to offer innovative outlooks"/>
  <result pre="intelligent, sensitive and specific nano-objects for in situ and real-time" exact="detection" post="of HIV. 5. Current Overview of Nanotechnology Use in"/>
  <result pre="The IC50 value of HPAC corresponding to HSV-1 and HSV-2" exact="infection" post="in prophylactic administration was found of 0.8 and 1"/>
  <result pre="using a murine model of ocular (HSV-1) and genital (HSV-2)" exact="infection" post="were performed. As a result, the ACV loaded HPAC"/>
  <result pre="syncytial virus (RSV), dengue and lenti virus. The in vivo" exact="testing" post="on Balb/c mice infected with RSV reveals the efficacy"/>
  <result pre="Balb/c mice infected with RSV reveals the efficacy of MUS:OT-NPs" exact="treatment" post="that prevented the pulmonary dissemination of the infection. These"/>
  <result pre="to cross cell membranes. Both in vivo and in vitro" exact="tests" post="on cell cultures have proven the lack of toxicity"/>
  <result pre="NNRTIs, include some of the drugs often used in HIV" exact="treatment" post="plans. Recently, Grande et al. [175] published a complex"/>
  <result pre="the NPs and a good stability. In vitro drug release" exact="tests" post="indicate that NPs can support the drug delivery for"/>
  <result pre="fluid phosphate buffer solution, physiological serum and distilled water; the" exact="tests" post="have been developed at 37 °C for 24 h."/>
  <result pre="SQV-PEO-PCL has been noticed. NFV, used in HIV-1 and HIV-2" exact="treatment" post="as PI, is a promising drug that can be"/>
  <result pre="(STP909), a nanobased drug candidate, which incorporates siRNA for the" exact="treatment" post="of HPV16 and HPV18; DermaVir from Genetic Immunity, a"/>
  <result pre="immune response in HIV-1-infected adults who are currently receiving anti-HIV" exact="treatment" post="(number NCT00270205) [194]; Doravirine (MK-1439), from Merck, a novel,"/>
  <result pre="interact with viral glycoproteins, shield virus surfaces, and efficiently block" exact="infection" post="since they act as robust inhibitors for these viruses."/>
  <result pre="safe antiviral nano-formulations to patients. 8. Conclusions Treating or improving" exact="treatment" post="success rate for viral diseases are fundamental responsibilities. The"/>
  <result pre="two costing approachesBMC Infect. Dis.20011510.1186/1471-2334-1-511472635 8.GonzaloT.García GoñiM.Muñoz-FernándezM.A.Socio-economic impact of antiretroviral" exact="treatment" post="in HIV patients. An economic review of cost savings"/>
  <result pre="of severe pneumonia requiring hospital admission in children without HIV" exact="infection" post="from Africa and Asia: The PERCH multi-country case-control studyLancet201939475777910.1016/S0140-6736(19)30721-431257127"/>
  <result pre="Prevention of Cytomegalovirus Infection and Disease in Transplant RecipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 56.SchreiberA.HärterG.SchubertA.BunjesD.MertensT.MichelD.Antiviral" exact="treatment" post="of cytomegalovirus infection and resistant strainsExp. Opin. Pharmacother.20091019120910.1517/1465656080267813819236193 57.De"/>
  <result pre="Infection and Disease in Transplant RecipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 56.SchreiberA.HärterG.SchubertA.BunjesD.MertensT.MichelD.Antiviral treatment of cytomegalovirus" exact="infection" post="and resistant strainsExp. Opin. Pharmacother.20091019120910.1517/1465656080267813819236193 57.De ClercqE.Antiviral agents active"/>
  <result pre="Engl. J. Med.20053532667267210.1056/NEJMoa05451216371632 64.TeH.S.RandallG.JensenD.M.Mechanism of action of ribavirin in the" exact="treatment" post="of chronic hepatitis CGastroenterol. Hepatol.20073218225 65.KrečmerováM.Amino Acid Ester Prodrugs"/>
  <result pre="Retrovirus InfectionsClin. Microbiol. Rev.20031656959610.1128/CMR.16.4.569-596.200314557287 67.LeeH.W.ParkJ.Y.AhnS.H.An evaluation of entecavir for the" exact="treatment" post="of chronic hepatitis B infection in adultsExp. Rev. Gastroenterol."/>
  <result pre="evaluation of entecavir for the treatment of chronic hepatitis B" exact="infection" post="in adultsExp. Rev. Gastroenterol. Hepatol.20161017718610.1586/17474124.2016.1125781 68.MatthewsS.Telbivudine for the management"/>
  <result pre="of chronic hepatitis B virus infectionClin. Ther.2007292635265310.1016/j.clinthera.2007.12.03218201580 69.AmarapurkarD.N.Telbivudine: A new" exact="treatment" post="for chronic hepatitis BWJG200713615010.3748/wjg.v13.i46.615018069753 70.Antiretroviral Drugs Used in the"/>
  <result pre="the blood brain barrier is vital property of neurotropic viral" exact="infection" post="of the central nervous systemActa Virol.201862162710.4149/av_2018_10229521099 110.SagarV.Pilakka-KanthikeelS.PottathilR.SaxenaS.K.NairM.Towards nanomedicines for"/>
  <result pre="bioinspired nanoparticles for targeted drug deliveryTher. Deliv.2017828929910.4155/tde-2017-001328361608 121.MuthuM.S.SinghS.Targeted nanomedicines: Effective" exact="treatment" post="modalities for cancer, AIDS and brain disordersNanomedicine2009410511810.2217/17435889.4.1.10519093899 122.LiuY.ChenC.Role of"/>
  <result pre="Blood in PrimatesAIDS Res. Hum. Retrovir.20153110711410.1089/aid.2014.021025402233 163.Arca-LafuenteS.Martínez-RománP.Mate-CanoI.MadridR.BrizV.Nanotechnology: A reality for" exact="diagnosis" post="of HCV infectious diseaseJ. Infect.201910.1016/j.jinf.2019.09.010 164.FarzinL.ShamsipurM.SamandariL.SheibaniS.HIV biosensors for early"/>
  <result pre="diagnosis of HCV infectious diseaseJ. Infect.201910.1016/j.jinf.2019.09.010 164.FarzinL.ShamsipurM.SamandariL.SheibaniS.HIV biosensors for early" exact="diagnosis" post="of infection: The intertwine of nanotechnology with sensing strategiesTalanta202020612020110.1016/j.talanta.2019.12020131514868"/>
  <result pre="drug deliveryFuture Med. Chem.201571097110710.4155/fmc.15.5726132521 185.SinghL.KrugerH.G.MaguireG.E.M.GovenderT.ParboosingR.The role of nanotechnology in the" exact="treatment" post="of viral infectionsTher. Adv. Infect.2017410513110.1177/2049936117713593 186.BovierP.A.Epaxal®: A virosomal vaccine"/>
  <result pre="gp 120 Folding inhibitor HIV [129,130,131] In vivo resistance to" exact="infection" post="has been enhanced; anti-CCR5 siRNA Immunoliposomes diameter with average"/>
  <result pre="and −15 mv; Non-cytotoxic PLGA-nps (24 h and 48 h" exact="contact" post="of three different NPs concentrations with HCEC cell); GCV"/>
  <result pre="of cells (hela, huvecs, dendritic cells, macrophages) after 72 h" exact="contact" post="with three different concentrations of AM nanorods; AM HIV"/>
  <result pre="QR-Tf with different SQV concentrations non-cytotoxic after 6–48 h of" exact="contact" post="with BMVECs; SQV [154] Nanospheres - Cs Spherical NS"/>
  <result pre="mV; ACV encapsulation efficiency 86% Satisfactory Vero cell viability after" exact="contact" post="with NS; ACV HSV [155] Micelles - Cs-g-oligo(NiPAam) Copolymers"/>
 </snippets>
</snippetsTree>
